According to the research report titled ‘Global Human Embryonic Stem Cells Market Size study with COVID-19 Impact, by Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing), and Regional Forecasts 2020-2026’, available with Market Study Report, global human embryonic stem cells market is expected to register substantial growth during 2020-2026.
 

For those uninitiated, human embryonic stem cells are derived from blastocyst and can differentiate into various cell types in the human body. These cells can also replicate and produce non-regenerative tissues including myocardial and neural cells. Human embryonic stem cells are widely adopted for treating genetic and blood disorders, cancer, and other immune system ailments. They are also used in research activities for genetic diseases, early human development, and toxicology testing.
 

Growing demand for regenerative medicines and advancements in stem cell therapies are major factors driving the growth of global human embryonic stem cells industry. Rising number of toxicology tests and technological breakthroughs in developing embryonic stem cells using alternative methods are also aiding the market expansion.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2633134/
 

Increasing pervasive of genetic disorders coupled with business-centric approaches by companies such as strategic collaborations and innovative product launches are also further stimulating the industry outlook. In January 2019, for instance, Stemcell Technologies Inc. introduced an upgraded version of mTeSR™1, called mTeSR™ Plus, which is the stabilized feeder-free maintenance solution for iPS (induced pluripotent stem) and human ES (embryonic stem) cells. However, concerns regarding stem cell research may act as a restraining factor to the growth of the market.
 

In terms of application space, the market is segmented into toxicology testing, tissue engineering, stem cell biology research, and regenerative medicine.
 

From the regional frame of reference, worldwide human embryonic stem cells industry is divided into Latin America, Europe, North America, Asia-Pacific and Rest of the World with Mexico, Brazil, Canada, U.S., Germany, UK, Japan, India and China as the point of focus.
 

The report states that Asia-Pacific human embryonic stem cells industry is predicted to accumulate notable gains as well as register high CAGR during the forecast period.
 

Cynata Therapeutics Ltd., Kite Pharma, Lonza Group AG, PromoCell GmbH, ESI BIO Inc., CellGenix Technologie Transfer GmbH, Thermo Fisher Scientific Inc., Biotime Inc./Cell Cure Neurosciences Ltd., Stemcell Technologies Inc. and Astellas Pharma Inc./ Ocata Therapeutics are the major companies in global human embryonic stem cells market.